Testosterone Replacement Therapy Market is Projected to Grow Expeditiously: to Reach $2.24 Billion by 2029
Offering reliable and timely data, this report is a key resource for anyone building or refining their testosterone replacement therapy industry roadmap.
How Much Is The Testosterone Replacement Therapy Market Worth?
The testosterone replacement therapy market size has grown marginally in recent years. It will grow from $2.07 billion in 2024 to $2.11 billion in 2025 at a compound annual growth rate (CAGR) of 1.9%. The growth in the historic period can be attributed to rising incidence of hypogonadism, increased life expectancy, changing lifestyles, prevalence of diabetes and metabolic syndrome, patient preference for non-invasive therapies, growing male infertility concerns.
The testosterone replacement therapy market size is expected to see marginal growth in the next few years. It will grow to $2.24 billion in 2029 at a compound annual growth rate (CAGR) of 1.6%. The growth in the forecast period can be attributed to precision medicine approaches, increasing male wellness market, regulatory support, globalization of health services, health and fitness trends, changing societal attitudes. Major trends in the forecast period include innovations in delivery systems, telemedicine and remote monitoring, customized treatment plans, nutritional and lifestyle approaches, research on combination therapies.
Get your free sample today:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9235&type=smp
What Are The Current Leading Growth Drivers For Testosterone Replacement Therapy Market?
The rising testosterone deficiency is expected to drive the growth of the testosterone replacement therapy market. Testosterone deficiency also refers to hypogonadism, the condition of having low testosterone and a body is unable to make enough testosterone. Testosterone replacement therapy is used to raise the body’s testosterone levels in the physiological range reverse the effects of hypogonadism and treats symptoms such as reduced libido, erectile dysfunction, depressed mood, anemia, loss of muscle, and others. For instance, according to Western Michigan Urological Associate’s report in 2022, a US-based association that specializes in urology, approximately 13 million men in the United States suffer from low testosterone levels, which equals 1 in 4 males over the age of 30. Therefore, the rise in testosterone deficiency is driving the growth of the testosterone replacement therapy market.
Which Segment Accounted For The Largest Testosterone Replacement Therapy Market Share?
The testosterone replacement therapy market covered in this report is segmented –
1) By Product Type: Oral, Implants, Gel Or Creams, Patches, Buccal Adhesive, Parenteral, Other Products
2) By Indication: Hypogonadism, Autoimmune Conditions, Genetic Disorders, Sex Organ Surgeries, Other Indications
3) By Active Ingredient Type: Testosterone, Methyl Testosterone, Testosterone Undecanoate, Testosterone Enanthate, Testosterone Cypionate
4) By End User: Hospitals, Clinics, Other End-User
Subsegments:
1) By Oral: Tablets, Capsules
2) By Implants: Pellets
3) By Gel Or Creams: Transdermal Gels, Transdermal Creams
4) By Patches: Transdermal Patches
5) By Buccal Adhesive: Buccal Tablets
6) By Parenteral: Intramuscular Injections, Subcutaneous Injections
7) By Other Products: Nasal Sprays, Other Delivery Forms
Emerging Trends And Strategic Opportunities In The Testosterone Replacement Therapy Market
Major companies in the testosterone replacement therapy (TRT) market are focusing on innovative delivery methods, such as oral formulations and telemedicine platforms, to provide men experiencing low testosterone levels with accessible and effective treatment options that enhance overall health and well-being. PRIME is an oral testosterone replacement therapy (TRT) product designed to treat men with low testosterone levels by providing a non-invasive alternative to traditional injectable therapies. For instance, in March 2024, Mangoceuticals Inc., a US-based company that develops men's health and wellness products launched ‘PRIME’, an oral testosterone replacement therapy (TRT) powered by Kyzatrex,approved by the Food and Drug Administration, a US-based health agency.. Kyzatrex is an oral formulation of testosterone undecanoate, designed to treat adult males with conditions associated with hypogonadism. This development marks a significant advancement in the treatment of adult males suffering from hypogonadism, a condition characterized by low testosterone levels. This positions PRIME as a convenient option for individuals seeking effective TRT alternatives.
Which Are The Top Companies To Hold The Market Share In Testosterone Replacement Therapy Market?
Major companies operating in the testosterone replacement therapy market include AbbVie Inc., Acerus Pharmaceuticals Corporation, Antares Pharma Inc., Bayer Aktiengesellschaft, BioTE Medical LLC, Clarus Therapeutics Inc., Eli Lilly and Company, Endo International plc, Pfizer Inc., Teva Pharmaceutical Industries Limited, Acrux Limited, Actiza Pharmaceutical Inc., Aytu BioPharma Inc., Cipla Limited, Sun Pharmaceutical Industries Limited, Ferring Pharmaceuticals Holdings S.A., Mylan N.V., Bausch Health Companies Inc., Allergan plc, Sandoz International GmbH, Perrigo Company plc, Besins Healthcare
View the full testosterone replacement therapy market report here:
https://www.thebusinessresearchcompany.com/report/testosterone-replacement-therapy-global-market-report
Which Region Is Projected To Account For The Largest Share Of The Testosterone Replacement Therapy Market?
North America was the largest region in the testosterone replacement therapy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the testosterone replacement therapy market report during the forecast period. The regions covered in the testosterone replacement therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
#Contact Us:#
The Business Research Company
Market Research Reports
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info
#Follow Us On:#
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Comments
Post a Comment